Genentech CEO in, Editas CEO Out, & the Shutdown IPO?

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Sharpless in the Saddle, NIH Threatened Again, & PBMs Prep for Senate Scrutiny
Gottlieb Exits, Biogen’s Big Gene Therapy Buy, and Lilly’s Pre-Emptive Price Cut
Pharma Dodges Senate Bullet, Roche Pays $4.8B for Spark, & BMS-Celgene Deal Wobbles
The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout